SAN MATEO, Calif., Dec. 18, 2025 — Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company focused on metabolic and fibrotic diseases, announced positive results from a Phase 1 pharmacokinetic (PK) clinical trial evaluating a combination of denifanstat and resmetirom. The study demonstrated that the oral, once-daily combination was generally well tolerated, with no serious adverse events, and generated PK data that support further clinical development. Based on these results, Sagimet plans to advance the program toward a Phase 2 proof-of-concept trial in patients with metabolic dysfunction–associated steatohepatitis (MASH) and advanced fibrosis (F4).
Science Significance
From a scientific standpoint, the results reinforce the rationale for combination therapy targeting complementary metabolic and fibrotic pathways in MASH. Denifanstat, a selective fatty acid synthase (FASN) inhibitor, reduces de novo lipogenesis and inflammation, while resmetirom, a thyroid hormone receptor beta (THR-β) agonist, enhances hepatic fat oxidation. The Phase 1 study evaluated single- and multiple-dose PK profiles and assessed potential drug–drug interactions, confirming that co-administration does not negatively impact exposure or safety. These findings support earlier preclinical evidence showing synergistic effects on liver disease biomarkers, strengthening the scientific foundation for combining mechanisms to address both fibrosis progression and metabolic dysfunction in advanced MASH.
Regulatory Significance
The trial represents an important regulatory milestone under good clinical practice (GCP) standards. Phase 1 PK studies are critical for informing dose selection, safety margins, and interaction risk before advancing into patient populations with significant comorbidities. The absence of serious adverse events or clinically meaningful laboratory abnormalities de-risks the program as Sagimet prepares to consult with regulatory authorities on the design of a Phase 2 study. For regulators, robust PK and tolerability data are essential to justify progression into cirrhotic (F4) MASH patients, a vulnerable population with high unmet medical need and limited approved treatment options.
Business Significance
Advertisement
Strategically, the announcement strengthens Sagimet’s clinical and commercial positioning in the competitive MASH landscape. While therapies exist for earlier disease stages, no approved treatments are available for MASH cirrhosis (F4). Advancing a differentiated combination therapy targeting this population could unlock significant market potential. The results also support Sagimet’s plan to develop a convenient fixed-dose, once-daily oral tablet, improving patient adherence and commercial viability. Combined with the company’s recent global license agreement for resmetirom API, the Phase 1 success underscores Sagimet’s execution capability and enhances its appeal to partners and investors focused on late-stage liver disease.
Patients’ Significance
For patients, particularly those living with MASH-related cirrhosis, the implications are meaningful. This population faces high risks of liver decompensation, hepatocellular carcinoma, and transplantation, with limited therapeutic options. A well-tolerated oral combination therapy designed to address both fibrosis and metabolic drivers could represent a major advance in disease management. By potentially slowing or reversing disease progression, such a therapy may improve long-term outcomes, quality of life, and survival, while reducing the need for invasive interventions.
Policy Significance
At the policy level, the development aligns with broader healthcare priorities aimed at addressing chronic liver disease and metabolic disorders, which place a growing burden on healthcare systems worldwide. Regulators and policymakers increasingly emphasize the importance of innovative combination therapies and evidence-based progression through clinical phases. Advancing treatments for advanced MASH also supports public health goals by potentially reducing downstream costs associated with liver failure, transplantation, and cancer care. The program exemplifies how science-driven, compliant clinical development can address areas of high unmet need.
Sagimet Biosciences’ positive Phase 1 PK results for the denifanstat and resmetirom combination mark a critical step toward addressing one of the most challenging stages of MASH. By demonstrating safety, tolerability, and supportive PK profiles, the company has laid the groundwork for regulatory engagement and Phase 2 clinical evaluation in cirrhotic patients. For the cGxP.wire audience, this development highlights the importance of rigorous early-phase clinical execution, regulatory readiness, and strategic combination design in advancing novel therapies for complex metabolic diseases.
Source: Sagimet Biosciences press release
